Immunotherapy for type 1 diabetes
- First Online:
- Cite this article as:
- Frumento, D., Ben Nasr, M., El Essawy, B. et al. J Endocrinol Invest (2017). doi:10.1007/s40618-017-0641-y
Although many approaches have been tested to overcome the insulin dependence caused by the pancreatic β-cells destruction observed in individuals affected by type 1 diabetes (T1D), medical research has largely failed to halt the onset or to reverse T1D.
In this work, the state of the art of immunotherapy will be examined, and the most important achievement in the field will be critically discussed. Particularly, we will focus on the clinical aspect, thus avoiding the tedious preclinical work done in NOD mice, which has been so poorly translated to the bedside.
Stem cell therapies achieved thus this far the most promising results, while immune ablation and standard immunosuppressants did not maintain the premises of preclinical results. The next step will be to generate a feasible and safe clinical approach in order to cure the thousands of patients affected by T1D.
KeywordsType 1 diabetes Immunotherapy Trials Clinical
|Funder Name||Grant Number||Funding Note|
|Fondazione Romeo ed Enrica Invernizzi|